Sentrx, the leading provider of drug safety services to the life sciences industry, has appointed Charles T. Saldarini as Chief Executive Officer and Chairman of the Board. Saldarini is a proven leader in the field of biopharmaceutical outsourcing services. He spent 18 year at PDI, Inc., rising to the position of CEO as he established the company as the leader in contract sale services.
Little Falls, NJ (PRWEB) April 16, 2009 -- Sentrx, the leading provider of drug safety services to the life sciences industry, is pleased to announce the appointment of Charles T. Saldarini as Chief Executive Officer and Chairman of the Board.
"Charles Saldarini is a proven leader in biopharmaceutical services and an innovator in the field of outsourcing," said John Martinson, Managing Partner of Edison Venture Capital, the primary investor in Sentrx. "His vision will bring Sentrx to its next level of growth."
Saldarini began his career as a Sales Representative for Merrill-Dow Pharmaceuticals. He soon moved to the entrepreneurial environment of PDI, Inc. (NASDAQ: PDII), one of the industry's first contract sales organizations, at the company's inception. Saldarini established PDI as a strategic option for biopharmaceutical companies. He built a highly professional contract sales service that was the first to match the industry standards for quality and effectiveness while offering a significantly reduced cost per representative. His passion to create new market approaches and expand service offerings allowed PDI to achieve high levels of client acquisition, retention and satisfaction.
During his 18-year tenure, Saldarini drove its growth in annual revenue from $1M to $365M. Saldarini's leadership enabled a successful public capitalization in 1998, f
Copyright©2009 Vocus, Inc.
All rights reserved